Skip to main content

Advertisement

Table 2 Reasons for discontinuation of abatacept infusion in the abatacept monotherapy group and the abatacept plus conventional DMARDs group

From: Abatacept monotherapy compared with abatacept plus disease-modifying anti-rheumatic drugs in rheumatoid arthritis patients: data from the ORA registry

  Abatacept monotherapy (n = 46) Abatacept + conventional DMARD (n = 90)
Primary ineffectiveness, n (%) 19 (41.3 %) 40 (44.4 %)
Therapeutic escape, n (%) 3 (6.6 %) 9 (10 %)
Infusion reaction, n (%) 2 (4.3 %) 1 (1.1 %)
Other side effects, n (%) 4 (8.7 %) 6 (6.7 %)
Unknown, n (%) 18 (39.1 %) 34 (37.8 %)
  1. DMARDs disease-modifying anti-rheumatic drugs